VYGR Voyager Therapeutics, Inc.
Nasdaq · SEC CIK 1640266 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $334.6K 12 sales by 4 insiders
- Filings on record
- 155 since 2021-11-30, latest 2026-06-11 16:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Sandrock Alfred | Pres, CEO, Dir | — | $184.4K |
| Swartz Robin | COO, CBO | — | $55.3K |
| Jorgensen Nathan D. | CFO | — | $54.2K |
| Carter Todd Alfred | CSO | — | $40.6K |
| Shiferman Gregory L. | SVP, GC | — | — |
| Ferguson Toby | Chief Medical Off | — | — |
Transactions 110
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-22 | 2022-02-17 | VYGR | Hesslein Robert W. | GC, Senior VP | S - Sale | $3.55 | -4,100 | 122.7K | -3% | -$14.6K | |
| 2022-02-15 | 2022-02-11 | VYGR | Hesslein Robert W. | GC, Senior VP | S - Sale | $3.36 | -3,252 | 126.8K | -3% | -$10.9K | |
| 2022-02-15 | 2022-02-11 | VYGR | Burek Julie | VP, Fin | S - Sale | $3.36 | -361 | 55.9K | -0.6% | -$1,213 | |
| D | 2022-01-18 | 2022-01-13 | VYGR | Higgins Michael J | CEO, Interim Pres, Dir | A - Grant | $0.00 | +45.2K | 45.2K | New | $0 |
| D | 2022-01-18 | 2022-01-13 | VYGR | PIERCE GLENN | Interim CSO, Dir | A - Grant | $0.00 | +26.3K | 26.3K | New | $0 |
| D | 2022-01-18 | 2022-01-13 | VYGR | Burek Julie | VP, Fin | A - Grant | $0.00 | +10.0K | 56.3K | +22% | $0 |
| D | 2022-01-18 | 2022-01-13 | VYGR | Hesslein Robert W. | GC, Senior VP | A - Grant | $0.00 | +20.0K | 130.1K | +18% | $0 |
| M | 2022-01-14 | 2022-01-03+ | VYGR | Burek Julie | VP, Fin | S - Sale | $2.85 | -3,328 | 46.3K | -7% | -$9,479 |
| 2022-01-14 | 2021-12-31 | VYGR | Burek Julie | VP, Fin | A - Grant | $2.30 | +3,063 | 49.6K | +7% | +$7,045 | |
| D | 2021-11-30 | 2021-11-26 | VYGR | Burek Julie | VP, Fin | A - Grant | $0.00 | +13.5K | 46.5K | +41% | $0 |
Purchase Sale Sale after option exercise All abbreviations